Furthermore, the identified DCT-compounds that bound with all investigated crystal complexes of PDE4D and PPARG are significant justifications for the historical clinical evidence of DCT reducing the symptoms of bronchoconstriction and airway inflammation, as we know these are the outcomes of registered asthma pharmaceutical compounds theophylline (PDE4D antagonist), ibudilast (PDE4D antagonist) and rosiglitazone (PPARG agonist). This evidence concerns the gene PPARG and asthma.